Effects of levocarnitine combined with telmisartan on cardiac output,peripheral blood TIPE2 level and exercise endurance in patients with hypertension and heart failure
Objective To explore the effects of levocarnitine combined with telmisartan on cardiac output(CO),peripheral blood tumor necrosis factor α induced protein 8 like molecule 2(TIPE2)level and exercise en-durance in patients with hypertension and heart failure.Methods A total of 88 patients with hypertension and heart failure treated in First People's Hospital of Linping District from August 2022 to March 2023 were selected and divided into an observation group and a control group according to treatment methods,44 cases in each group.The observation group was treated with levocarnitine and telmisartan,while the control group was treated with lev-ocarnitine.Com-pared the clinical efficacy,cardiac function indicator,peripheral blood TIPE2 level,exercise en-durance indicator,and adverse reactions between the two groups.Results After treatment,the clinical efficacy of the control group(77％)was lower than that of the observation group(95％)(x2=4.728,P=0.030).After treatment,the improvement levels of CO and LVEF[CO:(4.4±1.0)L/min;LVEF:(41.8±3.2)％and the decline level of LVEDD(43.8±7.1)min in the control group were significantly lower than those in the observation group[CO:(5.2±1.0)Umin;LVEF:(49.0±3.4)％;LVEDD:(40.2±6.5)mm(CO:t=3.740,P＜0.01;LVEF:t=14.991,P＜0.01;LVEDD:t=18.954,P＜0.0 1).After treatment,the peripheral blood TIPE2 levels increased in both groups,and the increase rate in the control group(20.0±0.9)μg/L was significantly lower than that in the observation group(25.2±1.1)µg/L(t=23.937,P＜0.01).After treatment,both groups showed an increase in peak oxygen consumption(observation group:(16.1±2.1)min;control group:(15.1±2.2)m·kg-1·min-1,the longest exercise time(observation group:(7.6±1.3)min;control group:(7.0±1.2)m·kg-1·min-1,and 6MWT distance(observation group:(300±25)m;control group:(261±24)m,with more significant increases in various exercise endurance indicators in the observation group(peak oxygen consumption:t=2.116,P＜0.01;longest exercise time:t=2.438,P＜0.01;6MWT distance:t=7.409,P＜0.01).The incidence of adverse reactions in the observation group(1 case,2％)was significantly lower than that in the control group(8 cases,18％)(y2=4.456,P=0.035).Conclusion Levocarnitine combined with telmisartan can ef-fectively increase the CO level,peripheral blood TIPE2 level and exercise tolerance,reduce inflammatory response,and thus improve the patient's quality of life.
LevocarnitineTelmisartanHypertensionHeart failureTumor necrosis factor α-induced protein-8-like molecule 2Walk test
万方数据
维普
